These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 20609201)

  • 41. New therapies for immune thrombocytopenic purpura.
    Andemariam B; Bussel J
    Curr Opin Hematol; 2007 Sep; 14(5):427-31. PubMed ID: 17934347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rituximab-induced toxicity.
    Mumoli N; Cei M
    QJM; 2011 Mar; 104(3):265. PubMed ID: 20228132
    [No Abstract]   [Full Text] [Related]  

  • 43. Chronic immune thrombocytopentic purpura in children: assessment of rituximab treatment.
    Taube T; von Stackelberg A; Schulte-Overberg U; Henze G; Schmid H; Reinhard H
    J Pediatr; 2006 Mar; 148(3):423. PubMed ID: 16615988
    [No Abstract]   [Full Text] [Related]  

  • 44. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange.
    Chow KV; Carroll R; Branley P; Nicholls K; Becker G; Hogan C
    Intern Med J; 2007 May; 37(5):329-32. PubMed ID: 17504282
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful treatment with Rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin's lymphoma.
    Shvidel L; Klepfish A; Berrebi A
    Am J Hematol; 2001 Jul; 67(3):213-4. PubMed ID: 11391724
    [No Abstract]   [Full Text] [Related]  

  • 47. Rituximab for ITP: a long-term fix?
    Takemoto CM
    Pediatr Blood Cancer; 2009 Feb; 52(2):155-6. PubMed ID: 18985744
    [No Abstract]   [Full Text] [Related]  

  • 48. Rituximab and factors predictive of response in chronic immune thrombocytopenic purpura of children.
    Cesaro S; Bisogno G; Pusiol A
    J Pediatr; 2005 Nov; 147(5):715; author reply 715-6. PubMed ID: 16291374
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura.
    Moschovi M; Trimis G; Pergantou H; Platokouki H; Vrachnou E; Tzortzatou-Stathopoulou F
    J Paediatr Child Health; 2005 Jul; 41(7):384-6. PubMed ID: 16014149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weekly long-term intravenous immunoglobulin for refractory parvovirus B19 and Epstein-Barr virus-induced immune thrombocytopenic purpura.
    Tavil B; Unal S; Aytaç-Elmas S; Yetgin S
    Turk J Pediatr; 2008; 50(1):74-7. PubMed ID: 18365597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No evidences for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy.
    Toffoletti E; Zaja F; Chiarvesio A; Michelutti A; Battista M; Fanin R
    Haematologica; 2008 May; 93(5):795-6. PubMed ID: 18450740
    [No Abstract]   [Full Text] [Related]  

  • 52. [Commentary on "Rituximab in thrombocytopenic purpura..."].
    García-Álvarez JL
    Rev Med Inst Mex Seguro Soc; 2012; 50(4):351-2. PubMed ID: 23234734
    [No Abstract]   [Full Text] [Related]  

  • 53. [Reply to commentary on "Rituximab in thrombocytopenic purpura..."].
    Zambrano-Velarde MA; de la O-Peña D; Chávez-Peña Q; Bedolla-Barajas M
    Rev Med Inst Mex Seguro Soc; 2012; 50(4):353-4. PubMed ID: 23234735
    [No Abstract]   [Full Text] [Related]  

  • 54. Rituximab in children with idiopathic thrombocytopenic purpura: does it really work?
    Russo G; Licciardello M; La Spina M
    Eur J Pediatr; 2004 Sep; 163(9):569. PubMed ID: 15243812
    [No Abstract]   [Full Text] [Related]  

  • 55. [Immunologic mechanisms involved in rituximab failure during adult immune thrombocytopenia].
    Audia S; Saas P; Bonnotte B
    Med Sci (Paris); 2014 Mar; 30(3):239-42. PubMed ID: 24685209
    [No Abstract]   [Full Text] [Related]  

  • 56. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy.
    Ponte P; Lopes MJ
    J Am Acad Dermatol; 2010 Aug; 63(2):355-6. PubMed ID: 20633812
    [No Abstract]   [Full Text] [Related]  

  • 57. Are 25 antibodies better than 1?
    Cuker A
    Blood; 2012 Nov; 120(18):3627-8. PubMed ID: 23118211
    [No Abstract]   [Full Text] [Related]  

  • 58. Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT.
    Kanack AJ; Bayas A; George G; Abou-Ismail MY; Singh B; Kohlhagen MC; Splinter NP; Christ M; Naumann M; Moser KA; Smock KJ; Grazioli A; Wen R; Wang D; Murray DL; Padmanabhan A
    Blood; 2022 Jul; 140(1):73-77. PubMed ID: 35560046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple recurrence of acute idiopathic thrombocytopenic purpura.
    Takahashi T; Nakamura K; Sugiyama H; Imura H
    Acta Haematol; 1993; 90(3):162-4. PubMed ID: 8291378
    [No Abstract]   [Full Text] [Related]  

  • 60. Unfavorable course in pregnancy-associated thrombotic thrombocytopenic purpura necessitating a perimortem Cesarean section: a case report.
    González-Mesa E; Narbona I; Blasco M; Cohen I
    J Med Case Rep; 2013 Apr; 7():119. PubMed ID: 23628258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.